HOME >> BIOLOGY >> NEWS
Sidebar: new trial should lead to better understanding of why exercise is an effective treatment for depression

DURHAM, N.C. -- The Duke University Medical Center researchers who found evidence that exercise can be an effective treatment for major depression are embarking on a larger trial they believe will answer some of the remaining questions posed by their earlier results.

The new trial, which is being funded by a $3 million grant from the National Institute of Mental Health, is designed to further refine which depressed patients can benefit from exercise and determine why exercise appears to be effective. Additionally, the study will measure the effect of exercise on a phenomenon known as vascular depression, a form of depression that appears linked to actual abnormalities in blood vessels of the brain, and not brain chemical imbalances. The previous Duke studies, led by psychologist James Blumenthal, found that exercise was just as effective as the most common anti-depressive medication in reducing the symptoms of major depression.

"This new trial is intended to answer some of the whys' posed by those original studies," Blumenthal explained. "We are very interested in evaluating behavioral, non-pharmacologic approaches to treating depression. Because up to one-third of depressed patients may not respond to drug therapy, and those who do take drugs may complain of side effects, it is important to find other approaches."

Over the next five years, the researchers plan to enroll 216 volunteers, half of whom will be assigned randomly to the drug arm of the trial and half to the exercise arm. The drug to be used is sertraline (trade name Zoloft), a member of a class of commonly used anti-depressants known as selective serotonin reuptake inhibitors, and the same drug used in the earlier trials.

Unlike the earlier trials, the new trial will have a placebo, or ineffective sugar pill, arm. Also unlike the earlier trials, the exercise arm will be divided as well -- half of the patients will do thei
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
20-Sep-2000


Page: 1 2 3

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... , ... October 10, 2017 , ... Dr. Bob Harman, ... his local San Diego Rotary Club. The event entitled “Stem Cells ... and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human ...
Breaking Biology Technology:
Cached News: